Key Equity Research Analysts at H.C. Wainwright Kept their ‘Buy’ rating for Cardiome Pharma Corp (NASDAQ:CRME) Shares Today. Their TP Given is $9.5000

May 18, 2018 - By Bradley Stiles

Investors sentiment decreased to 0.46 in 2017 Q4. Its down 0.63, from 1.09 in 2017Q3. It fall, as 6 investors sold Cardiome Pharma Corp. shares while 7 reduced holdings. 2 funds opened positions while 4 raised stakes. 12.53 million shares or 7.45% less from 13.54 million shares in 2017Q3 were reported.

Renaissance Tech Ltd Liability Corporation owns 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME) for 486,613 shares. Alphaone Inv Service Ltd Com, a Pennsylvania-based fund reported 10,625 shares. Knott David M owns 67,978 shares. Virtu Fincl Limited invested in 0% or 11,693 shares. Art Advsrs Limited Liability invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Royal Financial Bank Of Canada holds 1,233 shares or 0% of its portfolio. Bank Of Montreal Can holds 504 shares or 0% of its portfolio. Rock Springs Cap Management Ltd Partnership accumulated 1.20 million shares or 0.08% of the stock. National Bank Of America De reported 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Pennsylvania-based Valley National Advisers has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Moreover, Putnam Invs Limited Liability Corporation has 0.01% invested in Cardiome Pharma Corp. (NASDAQ:CRME) for 3.09 million shares. Scotia Cap holds 19,120 shares. Group One Trading L P holds 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME) for 917 shares. Westfield Capital Mngmt Lp holds 0.06% or 4.68 million shares in its portfolio. Wells Fargo & Company Mn has 800 shares.

Cardiome Pharma Corp (NASDAQ:CRME) Rating Reaffirmed

H.C. Wainwright now has a $9.5000 PT on shares of Cardiome Pharma Corp (NASDAQ:CRME). The PT indicates a potential upside of 305.98 % from the last price of Cardiome Pharma Corp (NASDAQ:CRME). This rating was shown in an analyst note on 17 May.

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Among 2 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp has $9.5 highest and $2.8 lowest target. $6.15’s average target is 162.82% above currents $2.34 stock price. Cardiome Pharma Corp had 4 analyst reports since November 22, 2017 according to SRatingsIntel. The stock has “Buy” rating by Mackie on Wednesday, March 14. H.C. Wainwright maintained Cardiome Pharma Corp. (NASDAQ:CRME) rating on Wednesday, November 22. H.C. Wainwright has “Buy” rating and $9.5 target. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) has “Buy” rating given on Friday, December 15 by Mackie. The rating was maintained by H.C. Wainwright on Wednesday, April 4 with “Buy”.

The stock decreased 1.68% or $0.04 during the last trading session, reaching $2.34. About 90,444 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 27.63% since May 18, 2017 and is downtrending. It has underperformed by 39.18% the S&P500.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $81.10 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

More notable recent Cardiome Pharma Corp. (NASDAQ:CRME) news were published by: Benzinga.com which released: “Earnings Scheduled For May 15, 2018” on May 15, 2018, also Benzinga.com with their article: “Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference” published on April 26, 2018, Prnewswire.com published: “Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 …” on May 10, 2018. More interesting news about Cardiome Pharma Corp. (NASDAQ:CRME) were released by: Seekingalpha.com and their article: “Cardiome Pharma’s (CRME) CEO William Hunter on Q1 2018 Results – Earnings Call Transcript” published on May 16, 2018 as well as Seekingalpha.com‘s news article titled: “Cardiome up 13% premarket on United Therapeutics’ takeout of SteadyMed” with publication date: April 30, 2018.

Cardiome Pharma Corp. (NASDAQ:CRME) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: